Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The authors concluded that diazoxide reduces undesirable side effects compared to minoxidil while increasing elastic fiber content and decreasing cell number in the aorta, suggesting potential suitability for treating vascular conditions with low arterial elastin and hypertension.

This review explores potential early-stage pharmacologic interventions for COVID-19 by targeting virus entry into host cells, identifying several existing drugs for further investigation, but reports no new clinical results.

This review discusses the drug repurposing of cardiovascular medications like aspirin and statins for new uses, including potential anti-tumor effects, noting promising experimental outcomes but less conclusive clinical trials, particularly in the field of cancer treatment.

This review discusses the integration of drug repurposing with personalized medicine through off-label prescribing and reports no new results, highlighting the potential for systematic exploration using omics technologies.

This study found that the developed Finasteride-loaded SMEDDS improved the relative bioavailability of the drug compared to a commercial tablet, offering a promising oral delivery system for glucosteroid analogs.

In this study, complexation with cyclodextrins was reported to increase the solubility of FIN for potential use in aqueous formulations for treating male androgenic alopecia.

This study reviewed the dosages of products approved in Japan from 2003-2010 and found that 28.1% were at different levels than in the U.S., with limited evidence suggesting different clinical responses.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

At the 21st Royan International Stem Cell Congress, researchers highlighted the growing integration in regenerative medicine, emphasizing advances in pluripotency, AI applications, and bioengineering for the development of accessible stem cell therapies.

In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.

This review systematically evaluates Erzhi Pill's formulation, therapeutic potential, and challenges, exploring its traditional applications and modern prospects for developing integrated quality control and precise medical strategies.

In this case report, a 47-year-old man experienced systemic hair loss after starting hemodialysis, which resolved after discontinuing the antipruritic drug nalfurafine, suggesting its role in causing hair follicle capillary regression.

This research focused on formulating finasteride, dutasteride, and minoxidil with cyclodextrins to enhance their solubility and skin penetration for topical use, potentially reducing scalp irritation from current alcohol-based preparations.

This reference compilation details potential adverse skin reactions and other side effects associated with the antihypertensive drug Quinazil, including rare cases of skin angioedema and other dermatological reactions.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

This article describes an increase in the detection of heart failure among young people and discusses the development of the drug Uperio for its treatment and support.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

In this study, exposure to ARBs, ACE inhibitors, and thiazides was associated with an increased risk of various skin cancers, including melanoma and nonmelanoma types, highlighting potential clinical implications for antihypertensive treatment choices.

This review discusses several new pharmacological products, including those for cardiovascular prevention and overactive bladder, but notes challenges in defining their therapeutic roles and provides safety updates on existing medications; it reports no new clinical results.

This review discusses indole-based bifunctional aldose reductase inhibitors and antioxidants for diabetic complications and chronic inflammation-related pathologies, but reports no new clinical results.

This article highlights that rivaroxaban, commonly associated with bleeding risks, may also cause rare non-bleeding adverse effects like liver injury and hypersensitivity.

This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This study found that self-monitoring blood pressure among pregnant women with hypertension did not significantly improve clinical outcomes compared to usual care, though women reported positive cognitive and emotional responses.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

This case report details a probable severe adverse event associated with ritlecitinib for alopecia areata, highlighting risks of pulmonary emboli, infection, atrial fibrillation, and acute kidney injury despite an absence of known risk factors.

In this study, researchers found that niosomes, bilosomes, and spanlastic formulations can enhance the oral anticoagulation efficiency of rivaroxaban in rats, with spanlastic ranked as the most effective in prolonging clotting, prothrombin, and tail bleeding times compared to unprocessed rivaroxaban.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.